Sixty Degree Capital
Venture capitalNorth York · Pre-Seed–Late Stage · 17 people tracked
Investment thesis
Sixty Degree Capital pursues a thesis-driven strategy across healthcare and technology, seeking breakthrough opportunities capable of reshaping industries. Its technical team combines domain expertise, rigorous quantitative analysis, and hands-on operational support to identify the underlying trends driving durable, transformational change. In technology it targets AI, cybersecurity, digital infrastructure, and SaaS; in healthcare it covers drug development, diagnostics, digital health, and medical devices. The firm invests across stages from pre-seed to growth and emphasizes purposeful innovation, forward-thinking, precision, and transparency, while also channeling a portion of proceeds toward educational institutions, hospitals, and community organizations.
Source: firm website, verified Aug 3, 2026.
Team · 17 people
from the firm's website & public directories
What they invest in
from 8 of 23 portfolio companiesBiotech ×4Healthtech ×4AI & Machine Learning ×3Enterprise Software ×3Cloud Computing ×1Cybersecurity ×1Data & Infrastructure ×1Deep Tech ×1
HQs:United States×7Germany×1
Investments · 23 tracked
founders shown can be your intro pathHerndon, US
Simon Mark Davidson(Director)John Sheldon Serafini(Executive Officer, Director)Arthur Lewis Money(Director)David Farnsworth(Director)Jaye Alison Alfers(Executive Officer)Christopher Bradley DeMay(Executive Officer)
Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.
AI & Machine LearningBiotechDeep TechMedical Devices
Mathai Mammen(CEO, President and Chairman)
Clinical-stage gene therapy company developing AAV therapeutics for inherited retinal disorders.
Clinical-stage biotech developing dual-acting biologics for sustainable weight loss and maintenance.
Arcellx develops CAR T-cell therapies that are individually designed for each patient, using the immune system to target and attack cancer.
BiotechHealthtechGaithersburg, US
Han Lee(Executive Officer)Lewis T. Rusty Williams(Director)David Lubner(Director)Rami Elghandour(Executive Officer, Director)
BoardJill Carroll(Director)Ali Behbahani(Director)
Clinical-stage biotech developing TCR-mimetics recognizing intracellular tumor antigens for hematological and solid cancers.
Eclypsium provides hardware and firmware security solutions for enterprises to identify and address vulnerabilities in chips, low-level code, and digital supply chains.
CybersecurityDefense TechEnterprise SoftwareHardwarePortland, US
Yuriy Bulygin(Co-founder)Alex Bazhaniuk(Co-founder)John Ewert(Executive Officer)
BoardAlex Doll(Director)Timothy Porter(Director)
Chicago, US
Edward Bellis(Executive Officer, Director)Michael Roytman(Director)Jason Jacobs(Executive Officer)Stephen Ward(Director)
BoardJohn Cowgill(Director)
Oncology-focused pharmaceutical company developing first-in-class nuclear export inhibitors for cancer treatment.
Kinaset Therapeutics is a biopharmaceutical company developing respiratory drug therapies.
BiotechHealthtechMedfield, US
Tom King(Director of the Issuer)Roger Heerman(Chief Business/Operating Officer / Co-Founder)Frazer Morgan(Chief Development Officer / Co-Founder)Bram Vanparys(Director of the Issuer)Robert Clarke(Chief Executive Officer / Board Member / Co-Founder)Christopher O’Brien(Chief Medical Officer)
KnownWell provides virtual and in-person weight-inclusive healthcare for patients with overweight and obesity.
Digital HealthHealthtechWellness & FitnessNeedham, US
Ben Wanamaker(Director)Angela Fitch(Executive Officer)inBrooke Boyarsky Pratt(Executive Officer, Director)in
BoardVineeta Agarwala(Director)Ian Chiang(Director)
Digital asset exchange platform offering trading, derivatives, and institutional services with strong security and regulatory compliance.
Clinical-stage precision oncology company identifying novel druggable mutations via genomics and AI-driven platform.
PandasAI is an open-source library that lets users query data stored in dataframes, databases, or data lakes using natural language to perform analysis and generate visualizations without writing code.
AI & Machine LearningData & InfrastructureEnterprise SoftwareMunich, DE
Gabriele Venturi(Founder)in
Biotech company developing therapies for cancer and autoimmune diseases.
Biotech company developing next-generation non-viral gene delivery systems.
Space exploration and technology company developing rockets and spacecraft for human spaceflight and satellite deployment.
Clinical-stage biotech focused on engineered T-cell receptor therapies for solid tumor cancers.
Exits · 2
IPOs and acquisitions across the tracked portfolioHawkEye 360NYSE: HAWKParabilis MedicinesNASDAQ: PBLS
Portfolio news
latest coverage across their companiesEmpirical Security · theaiinsider.tech · Jul 29, 2026
Rafay · finance.yahoo.com · Jul 9, 2026
Parabilis Medicines · pharmexec.com · Jun 19, 2026
Eclypsium · securityweek.com · Mar 20, 2026
Frequently asked questions
- What stage does Sixty Degree Capital invest at?
- Sixty Degree Capital invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does Sixty Degree Capital focus on?
- Sixty Degree Capital focuses on AI & Machine Learning, Biotech, Cloud Computing, Cybersecurity, Data & Infrastructure, Developer Tools, Digital Health, Enterprise Software, Fintech, Healthtech, Medical Devices, SaaS.
- Where is Sixty Degree Capital located?
- Sixty Degree Capital is headquartered in North York, CA.
- Does Sixty Degree Capital lead rounds?
- Sixty Degree Capital typically participates in rounds rather than leading them.
Similar investors
DCVC (Data Collective) is a venture capital firm that backs founders building companies which apply technology to major challenges across areas such as energy, biotech, agriculture, and machine learning.
Khosla Ventures is a venture capital firm known for backing bold, contrarian bets in world-class teams that can reshape entire industries.
GV (formerly Google Ventures) is a venture investment firm that backs founders across many industries, aiming to build long-term relationships and support companies across multiple stages and milestones.
A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.
Bessemer Venture Partners is a venture capital firm that partners with entrepreneurs from early stages through every stage of growth, publishing investment roadmaps across multiple technology sectors.